Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

globenewswire

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions – NEWSnet – News… as it used to be

More Press Releases

May 6, 2026

South Star Announces Non-Brokered Private Placement

May 6, 2026

IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights

May 6, 2026

REGENCELL CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Regencell Bioscience Holdings Limited and Encourages Investors to Contact the Firm

May 6, 2026

Minister Champagne reaffirms government’s dedication to working with all payment industry stakeholders to accelerate national and economic prosperity: The Payments Canada SUMMIT